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ABSTRACT:
The efficacy of chemotherapy is often limited by side effects in normal tissues.  This 
is exemplified by cisplatin, a widely used anti-cancer drug that may induce serious 
toxicity in normal tissues and organs including the kidneys. Decades of research 
have delineated multiple signaling pathways that lead to kidney cell injury and 
death during cisplatin treatment.  However, the same signaling pathways may also 
be activated in cancer cells and be responsible for the chemotherapeutic effects of 
cisplatin in tumors and, as a result, blockade of these pathways is expected to reduce 
the side effects as well as the anti-cancer efficacy.  Thus, to effectively curtail the 
side effects, it is imperative to elucidate and target the cell killing mechanisms that 
are specific to normal (and not cancer) tissues. Our recent work identified protein 
kinase C δ (PKCδ) as a new and critical mediator of cisplatin-induced kidney cell 
injury and death. Importantly, inhibition of PKCδ enhanced the chemotherapeutic 
effects of cisplatin in several tumor models while alleviating the side effect in 
kidneys, opening a new avenue for normal tissue protection during chemotherapy.
INTRODUCTION
Cancer is the most devastating and intractable human 
disease. There are numerous ways to kill cancer cells, but 
most of them do not translate into cancer therapy because 
they kill normal cells and tissues as well. Thus selective 
and efficient targeting of cancer cells is the foremost goal 
in the development of anti-cancer therapeutics[1]. Most 
of the early anti-cancer therapies have some selectivity 
for cancer cells by inhibiting essential process like DNA 
replication and cell division in rapidly dividing cancer 
cells[1]. Recently developed anti-cancer drugs often have 
specific molecular targets that are deregulated in cancer 
cells[2]. The critical barrier in the use of early anti-cancer 
drugs is the development of resistance in cancer cells and 
the severe toxicity to normal tissues[3, 4]. It was believed 
that these impediments could be significantly reduced in 
the new generation of drugs that target specific molecular 
pathways in cancer tissues[2, 4]. However, it has been 
found that the new drugs often suffer from the same 
drawbacks[5]. 
Due to the side effect or toxicity in normal tissues, 
the therapeutic window of most anti-cancer agents is 
very narrow[6]. As a result, the anti-cancer drugs cannot 
be administered at the dosages where they can eradicate 
all the cancer cells. This is in part responsible for the 
selection of resistant cancer cells, ultimately leading to 
growth of tumors that are refractory to subsequent anti-
cancer therapy[6]. Although, the significance of resistance 
to anti-cancer drugs has been widely recognized and 
extensively studied[7, 8], the research on the mechanisms 
responsible for the toxicity to normal tissues has generally 
lagged far behind. The identification of molecular targets 
that reduce toxicity to normal tissues without blocking 
the anti-cancer effects has the potential to significantly 
improve the efficacy of chemotherapy. 
CISPLATIN AND NEPHROTOXICITY
Cisplatin is one of the oldest, highly effective and 
most commonly used anti-cancer drugs[9-11]. Cisplatin 
is a platinum based inorganic compound that is believed 
to cross-link DNA, leading to inhibition of essential 
processes like DNA replication and transcription[11]. Oncotarget 2012; 3:  107 - 111 108 www.impactjournals.com/oncotarget
Higher rate of DNA replication in rapidly proliferative 
cancer cells make them particularly sensitive to cisplatin-
induced DNA damage. Depending on the amount of 
DNA damage, cancer cells either repair/tolerate the 
DNA damage or undergo apoptosis in case of extensive 
damage[8]. Identification of resistant cells that have higher 
DNA repair or reduced DNA damage response/apoptosis 
have provided the basis that DNA damage is the major 
mechanism of cisplatin-induced tumor cell death[8, 12].
Along with its effectiveness in killing cancer cells, 
cisplatin has a wide range of side-effects in normal tissues, 
among which nephrotoxicity is most notable due to its 
potentially fatal nature[13, 14]. Cisplatin treatment can 
lead to severe kidney damage resulting in acute kidney 
injury, which has a very high rate of mortality[14]. 
Extensive hydration in patients can partially reduce the 
extent of kidney injury, however nephrotoxicity remains a 
main threat[13, 14]. Development of novel drugs derived 
from cisplatin like carboplatin and oxaloplatin have 
reduced toxicity, but these drugs are not as widely effective 
as cisplatin[13]. New strategies that reduce kidney injury 
during cisplatin treatment could have significant impact on 
the overall efficiency of chemotherapy.
Extensive studies have been conducted in the last 
decade to decipher the patho-physiological basis of 
cisplatin nephrotoxicity[13-17]. The major pathological 
feature of cisplatin-induced kidney injury is the cell 
death of renal tubular cells in the form of apoptosis and 
necrosis[13]. The specific sensitivity of tubular cells to 
cispatin is partly attributed to the fact that they accumulate 
many-fold higher amounts of cisplatin than other cells and 
tissues. Depending on the amount of cisplatin exposed, 
renal tubular cells undergo necrosis or apoptosis[18]. 
Along with renal cell death, an inflammatory component 
is also responsible for aggravating kidney injury[16, 
19-22].  Injured  kidney  cells  activate  inflammatory 
processes, which further increase renal cell death leading 
to extensive kidney injury and acute renal failure[19]. 
Genetic and pharmacological strategies that inhibit both 
renal  apoptotic  pathways  and  inflammation  in  renal 
tissues  provide  significant  protection  during  cisplatin 
treatment[13]. Other pharmacological/natural compounds 
that inhibit these processes indirectly also reduce cisplatin-
induced kidney injury[13]. These studies have thus 
provided insight into the complex molecular mechanisms 
responsible for cisplatin nephrotoxicity. At the same time, 
it has been proposed that these strategies could have 
potential renoprotective effects during cisplatin-based 
chemotherapy.
However, the most critical issue that has not been 
addressed is the effect of these protective strategies on 
the  anti-cancer  efficacy  of  cisplatin.  Indeed,  some  of 
the signaling pathways, for example the DNA damage 
response leading to p53 activation, observed in renal cells, 
also contribute to cisplatin mediated cancer cell death[23]. 
Identification  of  targets  that  can  reduce  renal  toxicity 
without blocking the anti-cancer efficacy of cisplatin could 
have important clinical significance.
IDENTIFICATION OF PKCΔ AS TARGET 
FOR  RENOPROTECTION  DURING 
CISPLATIN-BASED CHEMOTHERAPY
Protein kinase C (PKC) comprises of a family of 
highly conserved serine/threonine kinases that influence a 
wide range of cellular processes[24]. PKCδ is a member of 
the novel PKC sub-family, that are activated in a calcium-
independent, but diacylglycerol-dependent manner[25, 
26]. PKCδ is widely expressed in multiple tissues and 
has been implicated in a plethora of cellular processes 
including proliferation and apoptosis[25, 27, 28]. 
Knockout of PKCδ does not affect have overt effects on 
murine development, suggesting that PKCδ is not essential 
for normal mammalian development[29].
PKCδ is not only activated by cofactors, such as 
diacylglycerol and phorbol esters, but its activation is also 
dependent on post-translational modifications, especially 
phosphorylation[29]. Several tyrosine kinases, including 
growth factor receptors, Src family tyrosine kinases and 
c-Abl, have been implicated in PKCδ phosphorylation[29]. 
In addition PKCδ can be cleaved by caspases to generate 
a constitutively active catalytic fragment[25]. Numerous 
studies have thus implicated PKCδ activation as a pro-
apoptotic mechanism during various stimuli, including 
treatment with anti-cancer agents[29]. Intriguingly, PKCδ 
can also function as an anti-apoptotic factor and confer 
resistance to anticancer drugs. Furthermore, PKCδ is pro-
survival factor in several cancers[29]. Thus, depending 
on the treatment and cellular context, PKCδ may play 
contrasting roles in the decision of cell death or survival. 
The  mechanisms  underlying  the  dual  roles  of  PKCδ 
remain unclear, but the localization, phosphorylation 
status and downstream substrates may be involved. 
The lack of severe phenotype of PKCδ-deficient mice 
suggested that PKCδ might be dispensable for normal 
development and tissue maintenance[29]. However, PKCδ 
may play regulatory roles in cell stress and pathological 
conditions including treatment with anti-cancer drugs. 
Indeed our recent study[30] has identified a novel role 
of PKCδ during cisplatin-induced kidney injury. Genetic 
ablation and pharmacological inhibition of PKCδ provided 
significant  renal  protection  during  cisplatin  treatment 
in in vitro cell cultures and in vivo murine models[30]. 
Mechanistically, PKCδ was shown to be activated in a 
Src-dependent manner leading to downstream activation 
of MAPK pathway. 
While our study suggested a renal protective strategy 
during cisplatin chemotherapy by targeting PKCδ, we were 
however concerned that PKCδ inhibition might attenuate 
the anti-cancer efficacy of cisplatin in tumors. To address 
this key issue, we conducted a series of in vitro and in vivo 
experiments to determine the effect of PKCδ inhibition Oncotarget 2012; 3:  107 - 111 109 www.impactjournals.com/oncotarget
on the anti-cancer efficacy of cisplatin. Intriguingly, we 
found that PKCδ inhibition did not reduce the effect of 
cisplatin in cancer cells and in some cases PKCδ inhibition 
actually increased the chemotherapy efficacy. Importantly, 
we developed new in vivo mouse models in which both 
the anti-cancer efficacy of cisplatin and its toxicity or 
side effects in kidneys could be directly monitored. These 
experiments  demonstrated  unambiguously  that  PKCδ 
inhibition reduced cisplatin toxicity in normal tissues 
without diminishing its anti-cancer effects. As a matter of 
fact, in ovarian and breast tumor models, PKCδ inhibitors 
enhanced the cancer therapy effect of cisplatin (Figure 1).
The observed different effects of PKCδ inhibitors 
in kidneys and tumors remain enigmatic. Earlier studies 
implicated a pro-apoptotic role of PKCδ in both normal 
and cancer cells[29], leading to the suggestion that 
PKCδ may function as a tumor suppressor. However, 
direct  in vivo evidence for this theory is lacking and 
PKCδ-deficient  mice  do  not  display  any  propensity 
for carcinogenesis under normal conditions. In a 
recent study[31] the role of PKCδ in K-ras-dependent 
lung tumorigenesis was examined by using a mouse 
carcinogen model. Surprisingly, the incidence of urethane-
induced lung tumors was significantly reduced in PKCδ-
deficient mice compared with wild-type mice. PKCδ-KO 
tumors were smaller and showed significantly reduced 
proliferation.  It  is  suggested  that  PKCδ  may  act  as  a 
tumor promoter downstream of oncogenic K-ras during 
lung carcinogenesis. Unexpectedly, these studies indicate 
that the function of PKCδ in tumor cells may depend on 
specific oncogenic context, as loss of PKCδ suppressed 
growth only in the cells that depend on oncogenic K-ras 
for proliferation and survival. Consistently, a pro-survival 
role of PKCδ has been documented in several cancer cell 
lines[29]. 
How  can  these  seemingly  contradictory  findings 
be reconciled? We speculate that PKCδ may not have 
a critical pro-apoptotic or pro-survival role in normal 
mammalian development or physiological conditions. 
However, the cancer cells in some tumor types require 
PKCδ for survival and proliferation. Such scenario goes 
by the principle of ‘non-oncogenic addiction’[6] (Figure 
1). According to this model, activation of oncogenes 
and rapid proliferation in cancer cells induce a stress 
phenotype that is particularly sensitive to cellular stress 
[6]. As a result, the cancer cells become dependent on 
certain pathways for survival, which are non-essential in 
normal cells and tissues. These non-oncogenic pathways 
are not important for initial cancer development, but are 
critical for the survival and proliferation of cancer cells in 
tumors. PKCδ seems to be a good candidate protein for 
‘non-oncogenic addiction’ in cancer cells, which becomes 
essential for their survival under oncogenic stresses such 
as ras activation. If this is true, PKCδ could turn out to 
be an important target for anti-cancer therapy. Our study 
demonstrated a role of PKCδ in mediates the toxic effects 
of cisplatin in the kidneys and hence inhibition of PKCδ 
Figure  1:  PKCδ  inhibition  enhances  anti-cancer 
therapy  while  protecting  kidneys  during  cisplatin 
treatment.  Cisplatin induces cell death in both cancer and 
kidney cells, resulting in chemotherapy in tumors and acute 
kidney injury and kidney failure. Genetic or pharmacologic 
inhibition  of  PKCδ  enhances  the  chemotherapy  effect  of 
cisplatin in tumors and diminishes cisplatin-induced side effect 
in kidneys.
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Figure 2: PKCδ in survival of normal versus cancer cells.  PKCδ is not required for the survival normal cells. However, it is 
required for the survival and proliferation of cancer cells with an oncogenic stress phenotype and, as a result, suppression of PKCδ leads 
to cell injury and death in tumors.Oncotarget 2012; 3:  107 - 111 110 www.impactjournals.com/oncotarget
could reduce the toxicity and at the same time increase the 
anti-cancer efficacy of Cisplatin (Figure 2). 
CONCLUSIONS AND FUTURE 
 DIRECTIONS
Our recent studies have shed light on a hitherto 
under-appreciated yet important aspect of cancer therapy. 
Since the side effect or toxicity to normal tissues is one 
of the key determinants in the success of anti-cancer 
drugs,  identification  of  targets  and  development  of 
normal tissue protective strategies could have significant 
implications in the treatment of cancer. Several strategies 
have been developed to selectively kill certain types of 
cancer cells, while simultaneously protecting normal cells 
[32-44]. By including normal tissue specific-protective 
agents in chemotherapy, these strategies may increase 
the therapeutic window. In line with this idea, PKCδ has 
now been demonstrated to be a critical component in 
nephrotoxicity during cisplatin treatment. The fact that 
PKCδ might be a “non-oncogenic addiction” factor for 
cancer cell survival provides an immense opportunity 
to  increase  the  efficacy  of  chemotherapy  by  reducing 
the side effect in normal tissues and increasing the anti-
cancer effect in tumors. Studies in the future should 
further elucidate the differential functions of PKCδ and 
other potential ‘non-oncogenic addiction’ genes in normal 
versus cancer tissues, opening new avenues to improve the 
efficacy of cancer therapy. 
ACKNOWLEDGEMENTS
The work was supported by grants from the National 
Institutes of Health and Veterans Administration of the 
U.S.A.
REFERENCES
1.  Chabner BA, Roberts TG, Jr.: Timeline: Chemotherapy and 
the war on cancer. Nat Rev Cancer 2005; 5:65-72. 
2.  Cao Y, DePinho RA, Ernst M, Vousden K: Cancer research: 
past, present and future. Nat Rev Cancer 2011;11:749-754.
3.  Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 
2000; 100:57-70.
4.  Hanahan D, Weinberg RA: Hallmarks of cancer: the next 
generation. Cell 2011;144:646-674. 
5.  Verheul HM, Pinedo HM: Possible molecular mechanisms 
involved in the toxicity of angiogenesis inhibition. Nat Rev 
Cancer 2007; 7:475-485. 
6.  Luo J, Solimini NL, Elledge SJ: Principles of cancer 
therapy: oncogene and non-oncogene addiction. Cell 
2009;136:823-837. 
7.  Stewart DJ: Mechanisms of resistance to cisplatin and 
carboplatin. Crit Rev Oncol Hematol 2007; 63:12-31.
8.  Siddik ZH: Cisplatin: mode of cytotoxic action and 
molecular basis of resistance. Oncogene 2003; 22:7265-
7279. 
9.  Jamieson ER, Lippard SJ: Structure, Recognition, and 
Processing of Cisplatin-DNA Adducts. Chem Rev 1999; 
99:2467-2498. 
10.  Cohen SM, Lippard SJ: Cisplatin: from DNA damage to 
cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 
2001; 67:93-130.
11.  Ohndorf UM, Rould MA, He Q, Pabo CO, Lippard SJ: 
Basis for recognition of cisplatin-modified DNA by high-
mobility-group proteins. Nature 1999; 399:708-712. 
12.  Siddik ZH: Biochemical and molecular mechanisms of 
cisplatin resistance. Cancer Treat Res 2002; 112:263-284.
13.  Pabla N, Dong Z: Cisplatin nephrotoxicity: mechanisms and 
renoprotective strategies. Kidney Int 2008; 73:994-1007.
14.  Arany I, Safirstein RL: Cisplatin nephrotoxicity. Semin 
Nephrol 2003; 23:460-464. 
15.  Hodeify R, Megyesi J, Tarcsafalvi A, Safirstein RL, Price 
PM: Protection of cisplatin cytotoxicity by an inactive 
cyclin-dependent kinase. Am J Physiol Renal Physiol 2010; 
299:F112-120. 
16.  Ramesh G, Reeves WB: TNF-alpha mediates chemokine 
and cytokine expression and renal injury in cisplatin 
nephrotoxicity. J Clin Invest 2002;110:835-842.
17.  Cummings BS, Schnellmann RG: Cisplatin-induced renal 
cell apoptosis: caspase 3-dependent and -independent 
pathways. J Pharmacol Exp Ther 2002; 302:8-17. 
18. Pabla N, Murphy RF, Liu K, Dong Z: The copper 
transporter Ctr1 contributes to cisplatin uptake by renal 
tubular cells during cisplatin nephrotoxicity. Am J Physiol 
Renal Physiol 2009; 296:F505-511.
19. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB: 
Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 
2010; 2:2490-2518. 
20.  Ramesh G, Reeves WB: TNFR2-mediated apoptosis and 
necrosis in cisplatin-induced acute renal failure. Am J 
Physiol Renal Physiol 2003; 285:F610-618.
21.  Ramesh G, Zhang B, Uematsu S, Akira S, Reeves WB: 
Endotoxin and cisplatin synergistically induce renal 
dysfunction and cytokine production in mice. Am J Physiol 
Renal Physiol 2007; 293:F325-332.
22.  Zhang B, Ramesh G, Norbury CC, Reeves WB: Cisplatin-
induced nephrotoxicity is mediated by tumor necrosis 
factor-alpha produced by renal parenchymal cells. Kidney 
Int 2007; 72:37-44. 
23.  Palab N, Huang S, Mi QS, Daniel R, Dong Z: ATR-Chk2 
signaling in p53 activation and DNA damage response 
during cisplatin-induced apoptosis. J Biol Chem 20082; 
83:6572-6583. 
24.  Parker PJ, Murray-Rust J: PKC at a glance. J Cell Sci 2004; 
117:131-132.
25.  Kikkawa U, Matsuzaki H, Yamamoto T: Protein kinase C Oncotarget 2012; 3:  107 - 111 111 www.impactjournals.com/oncotarget
delta (PKC delta): activation mechanisms and functions. J 
Biochem 2002;132:831-839. 
26. Liu WS, Heckman CA: The sevenfold way of PKC 
regulation. Cell Signal 1998;10:529-542. 
27.  DeVries-Seimon TA, Ohm AM, Humphries MJ, Reyland 
ME: Induction of apoptosis is driven by nuclear retention 
of protein kinase C delta. J Biol Chem 2007; 282:22307-
22314. 
28. Humphries MJ, Ohm AM, Schaack J, Adwan TS, 
Reyland ME: Tyrosine phosphorylation regulates nuclear 
translocation of PKCdelta. Oncogene 2008; 27:3045-3053.
29.  Jackson DN, Foster DA: The enigmatic protein kinase 
Cdelta: complex roles in cell proliferation and survival. 
FASEB J 2004; 18:627-636.
30.  Pabla N, Dong G, Jiang M, Huang S, Kumar MV, Messing 
RO, Dong Z: Inhibition of PKCdelta reduces cisplatin-
induced nephrotoxicity without blocking chemotherapeutic 
efficacy  in  mouse  models  of  cancer.  J  Clin  Invest 
2011;121:2709-2722.
31.  Symonds JM, Ohm AM, Carter CJ, Heasley LE, Boyle 
TA, Franklin WA, Reyland ME: Protein kinase C delta is 
a downstream effector of oncogenic K-ras in lung tumors. 
Cancer Res 2011; 71: 2087-2097.
32.   Blagosklonny MV, Pardee AB. Exploiting cancer cell 
cycling for selective protection of normal cells. Cancer Res. 
2001; 61: 4301-4305.
33.    Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: 
protection of normal cells and unshielding of cancer cells. 
Cell Cycle. 2002; 1: 375-382.
34.   Blagosklonny MV, Robey R, Bates S, Fojo T.Pretreatment 
with DNA-damaging agents permits selective killing of 
checkpoint-deficient cells by microtubule-active drugs. J 
Clin Invest. 2000; 105:533-539.
35.  Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, 
Vassilev LT. Activation of p53 by MDM2 antagonists can 
protect proliferating cells from mitotic inhibitors. Cancer 
Res. 2005; 65: 1918-1924.
36.   Demidenko ZN, Halicka D, Kunicki J, McCubrey JA, 
Darzynkiewicz Z, Blagosklonny MV. Selective killing of 
adriamycin-resistant (G2 checkpoint-deficient and MRP1-
expressing) cancer cells by docetaxel. Cancer Res. 2005; 
65: 4401-4407.
37.    Demidenko ZN, An WG, Lee JT, Romanova LY, 
McCubrey JA, Blagosklonny MV. Kinase-addiction and 
bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-
expressing cells to imatinib and geldanamycin. Cancer Biol 
Ther. 2005; 4: 484-490.
38.    Apontes P, Leontieva OV, Demidenko ZN, Li F, 
Blagosklonny MV. Exploring long-term protection 
of  normal  human  fibroblasts  and  epithelial  cells  from 
chemotherapy in cell culture. Oncotarget. 2011; 2: 222-233.
39.   Darzynkiewicz Z. Novel strategies of protecting non-cancer 
cells during chemotherapy: are they ready for clinical 
testing? Oncotarget. 2011; 2: 107-108. 
40.  van Leeuwen IM, Laín S. Pharmacological manipulation 
of the cell cycle and metabolism to protect normal tissues 
against conventional anticancer drugs. Oncotarget. 2011; 2: 
274-276.
41.   Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler 
KW, Vogelstein B, Papadopoulos N. A panel of isogenic 
human cancer cells suggests a therapeutic approach for 
cancers with inactivated p53. Proc Natl Acad Sci U S A. 
2009;106: 3964-3969.  
42.   Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana 
L, Longo VD. Fasting and differential chemotherapy 
protection in patients. Cell Cycle. 2010; 9: 4474-4476.
43.   Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson 
AM, Lane DP, Lain S. Evaluation of an Actinomycin D/
VX-680 aurora kinase inhibitor combination in p53-based 
cyclotherapy. Oncotarget. 2010; 1: 639-650.
44.   Blagosklonny MV. NCI’s provocative questions on cancer: 
some answers to ignite discussion. Oncotarget. 2011; 2: 
1352-1367.